

**The Appendix is an integral part of  
Certificate of Accreditation No. 154/2022 of 25/03/2022**

**Accredited entity according to ČSN EN ISO 15189:2013:**

**Fakultní nemocnice Brno**

Internal Hematology and Oncology Clinic, Center of Molecular Biology and Gene Therapy  
Černoplní 212/9, 613 00 Brno

*The Laboratory has a flexible scope of accreditation permitted as detailed in the Annex. Updated list of activities provided within the flexible scope of accreditation is available at the Laboratory from the Quality Manager.*

**Examinations:**

| Ordinal number                                     | Examination procedure name  | Examination procedure identification | Examined object  |
|--|---|--------------------------------------|--|
| <b>802 - Medical Microbiology Laboratory</b>       |   |                                      |  |
| 1.   | Detection of CMV DNA by CMV HHV6,7,8 R-gene (Argene) diagnostic kit   | SA/CMBG/V0002                        | Biological material containing human nuclear DNA                               |
| 2.   | Examination of EBV DNA using EBV R-gene (Argene) diagnostic kit   | SA/CMBG/V0003                        | Biological material containing human nuclear DNA                               |
| <b>813 - Allergology and Immunology Laboratory</b> |   |                                      |  |
| 1.   | Detection of PNH clone characterized by the occurrence of combinations of GlyA <sup>+</sup> CD59 <sup>-</sup> or CD64 <sup>++</sup> 14 <sup>-</sup> Flaer <sup>-</sup> or CD15 <sup>+</sup> 24 <sup>-</sup> Flaer <sup>-</sup> surface antigens on peripheral blood cells by flow cytometry | SA/CMBG/F0001                        | Peripheral blood   |
| 2.   | Detection of CLL residual clone by flow cytometry according to modified Rawstron protocol <sup>8</sup>  | SA/CMBG/F0003                        | Peripheral blood, bone marrow  |
| <b>816 - Medical Genetics Laboratory</b>           |   |                                      |  |
| 1.   | Examination of karyotype of tumor cells by banding method   | SA/CMBG/C0001                        | Bone marrow, solid tumor tissue, peripheral blood, node                        |
| 2.   | Examination of constitutional karyotype by banding method   | SA/CMBG/C0003                        | Peripheral/umbilical cord blood, amniotic fluid, chorionic villi, fetal tissue |
| 3.   | Examination of acquired chromosomal aberrations by cytogenetic analysis of peripheral lymphocytes [ZCA, CAPL]   | SA/CMBG/C0004                        | Peripheral blood   |

**The Appendix is an integral part of  
Certificate of Accreditation No. 154/2022 of 25/03/2022**

**Accredited entity according to ČSN EN ISO 15189:2013:**

**Fakultní nemocnice Brno**

Internal Hematology and Oncology Clinic, Center of Molecular Biology and Gene Therapy  
Černopolní 212/9, 613 00 Brno

| Ordinal number | Examination procedure name   | Examination procedure identification | Examined object   |
|----------------|--|--------------------------------------|---|
| 4.             | Examination of chromosomal aberrations by fluorescent in-situ hybridization method [FISH]                              | SA/CMBG/C0002                        | Peripheral/umbilical cord blood, amniotic fluid, chorionic villi, fetal tissue, buccal smear, bone marrow, solid tumor tissue, node |
| 5.             | Examination of chromosomal aberrations by comparative genomic hybridization on oligonucleotide microarrays [array-CGH] | SA/CMBG/C0005                        | Peripheral/umbilical cord blood, amniotic fluid, chorionic villi, tissue, buccal smear, bone marrow, solid tumor tissue, node       |
| 6.             | Analysis of DNA by PCR method with electrophoretic detection of product <sup>1</sup>                                   | SA/CMBG/M1                           | Biological material containing human nuclear DNA  |
| 7.             | Detection of sequential variants in genes by Sanger sequencing <sup>2</sup>  | SA/CMBG/M2                           | Biological material containing human nuclear NA   |
| 8.             | Investigation of mutations in genes by massively parallel sequencing (NGS) <sup>3</sup>                                | SA/CMBG/M3                           | Biological material containing human nuclear DNA  |
| 9.             | Detection of sequential variants in genes by real-time PCR method <sup>4</sup>   | SA/CMBG/M4                           | Biological material containing human nuclear NA   |
| 10.            | Determination of genetic alterations by MLPA method <sup>5</sup>   | SA/CMBG/M5                           | Biological material containing human nuclear DNA  |
| 11.            | Analysis of fluorescently labelled DNA fragments by capillary electrophoresis method <sup>6</sup>                      | SA/CMBG/M6                           | Biological material containing human nuclear NA   |
| 12.            | Detection of sequential variants in genes by PCR method with reverse hybridization (strip-assay) <sup>7</sup>          | SA/CMBG/M7                           | Biological material containing human nuclear NA   |

**The Appendix is an integral part of  
Certificate of Accreditation No. 154/2022 of 25/03/2022**

**Accredited entity according to ČSN EN ISO 15189:2013:**

**Fakultní nemocnice Brno**

Internal Hematology and Oncology Clinic, Center of Molecular Biology and Gene Therapy  
Černoplní 212/9, 613 00 Brno

| Ordinal number | Examination procedure name   | Examination procedure identification | Examined object                                  |
|----------------|--|--------------------------------------|--|
| 13.            | Examination of cellular chimerism after allogeneic HSCT by fragment analysis method and RQ-PCR       | SA/CMBG/MO003                        | Biological material containing human nuclear DNA |
| 14.            | Examination of BCR-ABL1 fusion gene by Xpert BCR-ABL Ultra Kit (Cepheid) diagnostic kit <sup>9</sup> | SA/CMBG/MO006                        | Peripheral blood, bone marrow                    |
| 15.            | Examination of gene fusions and transcript variants with the AMLplexQS (Mentype) diagnostic kit      | SA/CMBG/MO007                        | Peripheral blood, bone marrow, RNA               |

Annex:

Flexible scope of accreditation

| Examination procedure ordinal numbers: |
|--|
| 6, 7, 8, 9, 10, 11, 12                 |

The Laboratory is allowed to modify the examination procedures listed in the Annex within the specified scope of accreditation provided the measuring principle is observed.

The flexible approach to the scope of accreditation cannot be applied to the examinations not included in the Annex.

Explanatory notes:

<sup>1</sup> Analysis of DNA by PCR method with electrophoretic detection of product:

|               |  |
|---------------|--|
| SA/CMBG/M1001 | Determination of sex [SRY]                           |
| SA/CMBG/M1002 | Celiac disease – genes DQB1, DQA1, DRB1 [HLA typing] |
| SA/CMBG/M1003 | Detection of fusion gene BCR::BLL1                   |

<sup>2</sup> Detection of sequential variants in genes by Sanger sequencing:

|               |  |
|---------------|--|
| SA/CMBG/M2001 | Retinoblastom [Rb1]  |
| SA/CMBG/M2002 | Non syndromic hearing loss [GJB2]  |
| SA/CMBG/M2003 | Phenylketonuria [PKU]  |
| SA/CMBG/M2004 | Wilson disease [ATP7B]   |
| SA/CMBG/M2005 | Determination of mutation state of IGVH gene                             |
| SA/CMBG/M2006 | Detection of mutations in the kinase domain of the fusion gene BCR::ABL1 |

**The Appendix is an integral part of  
Certificate of Accreditation No. 154/2022 of 25/03/2022**

**Accredited entity according to ČSN EN ISO 15189:2013:**

**Fakultní nemocnice Brno**

Internal Hematology and Oncology Clinic, Center of Molecular Biology and Gene Therapy  
Černoplní 212/9, 613 00 Brno

<sup>3</sup> Analysis of germinal mutations of genes:

LDLRAP1, ANGPTL3, APOB, ABCG5, ABCG8, MTTP, SAR1B, LPL, GPIHBP1, ABCA1, LIPA, APOA5, APOC3, APOA1, GPD1, SCARB1, LIPC, LMF1, CETP, LCAT, APOC2, AARS, ACTA1, ALG13, ALG2, ALS2, ANO5, AR, ATP1A2, BAG3, BICD2, BIN1, CACNA1S, CAPN3, CAV3, CFL2, CFTR, CLCN1, CNTN1, COL6A1, COL6A2, COL6A3, COLQ, CRYAB, CYP2CD, DAG1, DES, DMD, DNAJB6, DNM2, DOK7, DPM3, DYSF, EMD, EXOSC3, EXOSC8, FKR1, FKTN, FLNC, F8, GAA, GARS, GMPPB, GNE, CHKB, CHRNE, ISCU, ISPD, ITGA2B, ITGA7, KCNA1, KLHL40, KLHL41, KLHL9, LAMA2, LAMP2, LARGE, LBD3, LDB3, LMNA, LMOD3, MATR3, MSTN, MTM1, MYH2, MYH8, MYOT, NRAP, PABPN1, PIEZO2, PLEC, POLG, POLG2, POMGNT1, POMK, POMT1, POMT2, PTRF, RAPSN, RRM2B, SCN4A, SEPN1, SERPINE1, SGCA, SGCB, SGCD, SGCE, SGCG, SMCHD1, SPEG, SUCLA2, SYNE1, SYNE2, TCAP, TK2, TMEM43, TMEM5, TNNT1, TNPO3, TPM2, TPM3, TRAPPC11, TRIM32, TRIM63, TRPV4, TUBB3, UBA1, VAPB, VCP, VMA21, VKORC1, VPK1

<sup>4</sup> Detection of sequential variants in genes by real-time PCR method:

|               |  |
|---------------|--|
| SA/CMBG/M4001 | Factor V-Leiden – p.Arg506Gln  |
| SA/CMBG/M4002 | Factor II – Prothrombin – c.20210G>A                                   |
| SA/CMBG/M4003 | Lactose intolerance (LI) – LCT gene variants: -13910T/C a<br>-22018A/G |
| SA/CMBG/M4004 | Examination of fusion gene BCR-ABL from RNA <sup>a</sup>               |
| SA/CMBG/M4006 | Determination of mutations in <i>TPMT</i> gene                         |
| SA/CMBG/M4007 | Determination of mutations in <i>DPYD</i> gene                         |

<sup>5</sup> Determination of genetic alterations by MLPA method:

|               |  |
|---------------|--|
| SA/CMBG/M5001 | Duchenne muscular dystrophy [DMD]  |
| SA/CMBG/M5002 | Spinal muscular atrophy [SMN1, SMN2]                                     |
| SA/CMBG/M5003 | Léri-Weill dyschondrosteosis [SHOX]                                      |
| SA/CMBG/M5004 | Retinoblastom [RB1]  |
| SA/CMBG/M5005 | Detection of chromosomal aberrations<br>(microdeletion/microduplication) |
| SA/CMBG/M5006 | Phenylketonuria [PKU]  |

<sup>6</sup> Analysis of fluorescently labelled DNA fragments by capillary electrophoresis method:

|               |   |
|---------------|---|
| SA/CMBG/M6001 | Cystic fibrosis by ARMS method [CF EU 50 mt]. Variants R347P,<br>2789+5G>A, 3120+1G>A, 711+1G>T, R334W, I507del, F508del,<br>849+10kbC>T, 1078delT, W1282X, R560T, R553X, G551D, S<br>549RT>G, M1101K, G542X, 3905insT, S1251N, 1717-1G>A,<br>R117H, N1303K, G85E, 1898+1G>A, 2184delA, D1152H,<br>CFTRdele2,3, P67L, E60X, 3659delC, 621+1G>T, A455E,<br>R1162X, 394delTT, 444delA, R117C, Y122X, L206W, R347H,<br>677delTA, V520F, S549N, 1811+1.6kbA>G, 2143delT, 2347delG,<br>W846X, Q890X, 3272-26A>G, R1066C, 1092X(C>A) a R1158X,<br>IVS8-5T, IVS8-7T, IVS8-9T |
| SA/CMBG/M6002 | 13, 15, 16, 18, 21, 22, X, Y chromosome aneuploidies by QF<br>PCR method  |

**The Appendix is an integral part of  
Certificate of Accreditation No. 154/2022 of 25/03/2022**

**Accredited entity according to ČSN EN ISO 15189:2013:**

**Fakultní nemocnice Brno**

Internal Hematology and Oncology Clinic, Center of Molecular Biology and Gene Therapy  
Černopolní 212/9, 613 00 Brno

|                 |   |
|-----------------|---|
| SA/CMBG/M6003   | Determination of azoospermatic factor deletions by multiplex PCR method [AZF]   |
| SA/CMBG/M6004   | Hereditary hemochromatosis – detection of HFE gene variants p.C282Y, p.H63D, S65C   |
| SA/CMBG/M6005   | Fragile X syndrome – determination of the length of the CGG tract in 5'UTR of FMR1 gene   |
| SA/CMBG/M6006   | Myotonic dystrophy 1  |
| SA/CMBG/M6007   | Examination of NPM1 gene  |
| 7               | Detection of sequential variants in genes by PCR method with reverse hybridization (strip-assay):   |
| SA/CMBG/M7002   | Congenital adrenal hyperplasia (CAH) – gene variants CYP21A2 P30L, I2 splice (I2 G), Del 8 bp E3 (G110del8nt), I172N, Cluster E6 (I236N, V237E, M239K), V281L, L307 frameshift (F306 + T), Q318X, R356W, P453S, R483P   |
| SA/CMBG/M7003   | $\alpha$ -thalassemia<br>variants of the $\alpha$ -globin locus: -3.7 kb, -4.2kb, -20.5kb, -MED, -THAI, -FIL, $\alpha$ 1 codon 14 G>A, $\alpha$ 1 codon 59 G>A, anti – 3.7 triplication, $\alpha$ 2 initiation codon T>C, $\alpha$ 2 codon 59 G>A, $\alpha$ 2 codon 125 T>C, $\alpha$ 2 codon 142 T>C, $\alpha$ 2 codon 142 T>A, $\alpha$ 2 codon 142 A>T, $\alpha$ 2 codon 142 A>C, $\alpha$ 2 polyA-1 AATAAA>AATAAG, $\alpha$ 2 polyA-2 AATAAA>AATGAA<br>$\beta$ -thalassemia<br>variants of the $\beta$ -globin locus: sequence variants in position: -101 C>T, -87 C>G, -30 T>A, codon 5 -CT, codon 6 G>A, codon 6 A>T, codon 6 -A, codon8 -AA, codon 8,9 +G, codon 15 TGG>TGA, codon 27 G>T, codon 39 C>T, codon 44 -C, IVS 1.1 G>A, IVS 1.5 G>C, IVS 1.6 T>C, IVS 1.110 G>A, IVS 1.116 T>G, IVS 1.130 G>C, IVS 2.1 G>A, IVS 2.745 C>G, IVS 2.848 C>A. |
| 8 SA/CMBG/F0003 | Examined markers: CD3, CD5, CD19, CD20, CD22, CD43, CD45, CD79b, CD81   |
| 9 SA/CMBG/MO006 | Detected alterations: b2a2 (e13a2), b3a2 (e14a2)  |
| a SA/CMBG/M4004 | Detected alterations: b2a2 (e13a2), b3a2 (e14a2), e1a2, e19a2, b3a3 (e14a3) + rare alterations  |

*Abbreviations:*

|        |   |
|--------|---|
| HSCT   | - Hematopoietic stem cell transplantation |
| NGS    | - Next generation sequencing              |
| NA     | - Nucleic acid                            |
| PNH    | - Paroxysmal nocturnal hemoglobinuria     |
| RP PCR | - Repeat Primed PCR                       |
| RQ-PCR | - Real-Time Quantitative PCR              |
| RT     | - Reverse Transcription                   |